Vol 91, No 5 (2020)
Review paper
Published online: 2020-05-29

open access

Page views 1845
Article views/downloads 1280
Get Citation

Connect on Social Media

Connect on Social Media

GC-MS as a tool for reliable non-invasive prenatal diagnosis of Smith-Lemli-Opitz syndrome but essential also for other cholesterolopathies verification

Aleksandra Jezela-Stanek1, Anna Siejka2, Ewa M. Kowalska2, Violetta Hosiawa3, Malgorzata Krajewska-Walasek14
Pubmed: 32495936
Ginekol Pol 2020;91(5):287-293.

Abstract

Rare multiple congenital malformations/developmental disorders are challenging in clinical diagnosis. The introduction
of next-generation sequencing (NGS) has revolutionized this diagnostic by offering multigene panels or whole-exome
sequencing. However, if there is no possibility to perform NGS or if we are facing prenatal ultrasound results, clinical diagnostics
is even more difficult. For a selected group of congenital metabolic disorders, resulting from defects in cholesterol
biosynthesis (called cholesterolopathies), application of gas chromatography-mass spectrometry (GS-MS) may provide or
orientate diagnostics. The most common of these is Smith-Lemli-Opitz syndrome (SLOS), but in this publication, we also
want to introduce other cholesterolopathies and draw attention to the possibility of non-invasive prenatal diagnosis of SLOS.

Article available in PDF format

View PDF Download PDF file

References

  1. Miller W, Bose H. Early steps in steroidogenesis: intracellular cholesterol trafficking. Journal of Lipid Research. 2011; 52(12): 2111–2135.
  2. Wolf G. The function of cholesterol in embryogenesis. J Nutr Biochem. 1999; 10(4): 188–192.
  3. Baardman ME, Kerstjens-Frederikse WS, Berger RMF, et al. The role of maternal-fetal cholesterol transport in early fetal life: current insights. Biol Reprod. 2013; 88(1): 24.
  4. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res. 2011; 52(1): 6–34.
  5. Herman GE, Kratz L. Disorders of sterol synthesis: beyond Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 301–321.
  6. Nowaczyk MJM, Cunniff C. Smith-Lemli-Opitz syndrome and other disorders of cholesterol biosynthesis: An introduction. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 239–241.
  7. DeBarber AE, Eroglu Y, Merkens LS, et al. Smith-Lemli-Opitz syndrome. Expert Rev Mol Med. 2011; 13: e24.
  8. SMITH DW, LEMLI L, OPITZ JM. A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES. J Pediatr. 1964; 64: 210–217.
  9. Nowaczyk MJM, Irons MB. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 250–262.
  10. Martín MG, Pfrieger F, Dotti CG. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep. 2014; 15(10): 1036–1052.
  11. Batta AK, Salen G, Tint GS, et al. Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome. J Lipid Res. 1995; 36(4): 705–713.
  12. Porter FD. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet. 2008; 16(5): 535–541.
  13. Jezela-Stanek A, Ciara E, Małunowicz E, et al. Smith-Lemli-Opitz syndrome Collaborative Group. Differences between predicted and established diagnoses of Smith-Lemli-Opitz syndrome in the Polish population: underdiagnosis or loss of affected fetuses? J Inherit Metab Dis. 2010; 33 Suppl 3: S241–S248.
  14. Goldenberg A, Wolf C, Chevy F, et al. Antenatal manifestations of Smith-Lemli-Opitz (RSH) syndrome: a retrospective survey of 30 cases. Am J Med Genet A. 2004; 124A(4): 423–426.
  15. Haas D, Haege G, Hoffmann GF, et al. Prenatal presentation and diagnostic evaluation of suspected Smith-Lemli-Opitz (RSH) syndrome. Am J Med Genet A. 2013; 161A(5): 1008–1011.
  16. Shinawi M, Szabo S, Popek E, et al. Recognition of Smith-Lemli-Opitz syndrome (RSH) in the fetus: utility of ultrasonography and biochemical analysis in pregnancies with low maternal serum estriol. Am J Med Genet A. 2005; 138(1): 56–60.
  17. Quélin C, Loget P, Verloes A, et al. Phenotypic spectrum of fetal Smith-Lemli-Opitz syndrome. Eur J Med Genet. 2012; 55(2): 81–90.
  18. Ho ACC, Fung CW, Siu TS, et al. Lathosterolosis: a disorder of cholesterol biosynthesis resembling smith-lemli-opitz syndrome. JIMD Rep. 2014; 12: 129–134.
  19. Rossi M, Hall CM, Bouvier R, et al. Radiographic features of the skeleton in disorders of post-squalene cholesterol biosynthesis. Pediatr Radiol. 2015; 45(7): 965–976.
  20. Amaral C, Gallardo E, Rodrigues R, et al. Quantitative analysis of five sterols in amniotic fluid by GC-MS: application to the diagnosis of cholesterol biosynthesis defects. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(23): 2130–2136.
  21. Jira P. Cholesterol metabolism deficiency. Handb Clin Neurol. 2013; 113: 1845–1850.
  22. Kanungo S, Soares N, He M, et al. Sterol metabolism disorders and neurodevelopment-an update. Dev Disabil Res Rev. 2013; 17(3): 197–210.
  23. Guibaud L, Collardeau-Frachon S, Lacalm A, et al. Antenatal manifestations of inborn errors of metabolism: prenatal imaging findings. J Inherit Metab Dis. 2017; 40(1): 103–112.
  24. Anderson R, Rust S, Ashworth J, et al. Lathosterolosis: A Relatively Mild Case with Cataracts and Learning Difficulties. JIMD Rep. 2019; 44: 79–84.
  25. Whittock NV, Izatt L, Simpson-Dent SL, et al. Molecular prenatal diagnosis in a case of an X-linked dominant chondrodysplasia punctata. Prenat Diagn. 2003; 23(9): 701–704.
  26. Konstantinidou A, Karadimas C, Waterham HR, et al. Pathologic, radiographic and molecular findings in three fetuses diagnosed with HEM/Greenberg skeletal dysplasia. Prenat Diagn. 2008; 28(4): 309–312.
  27. Jezela-Stanek A, Małunowicz E, Anna S, et al. Trends in prenatal diagnosis of non-specific multiple malformations disorders with reference to the own experience and research study on Smith-Lemli-Opitz syndrome. Ginekol Pol. 2015; 86(8): 598–602.
  28. du Souich C, Raymond FL, Grzeschik KH. et al. NSDHL-Related Disorders. 2011 Feb 1 [Updated 2018 Oct 25]. In: Adam MP, Ardinger HH, Pagon RA. et al. ed. GeneReviews®. University of Washington, Seattle 1993-2019: [Internet].
  29. Frisso G, Gelzo M, Procopio E, et al. A rare case of sterol-C4-methyl oxidase deficiency in a young Italian male: Biochemical and molecular characterization. Mol Genet Metab. 2017; 121(4): 329–335.
  30. Baronio F, Ortolano R, Menabò S, et al. 46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features. Int J Mol Sci. 2019; 20(18).
  31. Rohanizadegan M, Sacharow S. Desmosterolosis presenting with multiple congenital anomalies. Eur J Med Genet. 2018; 61(3): 152–156.
  32. Prasun P, Ferguson E, Iverson A, et al. Lathosterolosis: An Extremely Rare Inherited Condition Associated With Progressive Liver Disease. J Pediatr Gastroenterol Nutr. 2019; 69(5): e142–e145.
  33. Shackleton CH, Roitman E, Kratz LE, et al. Midgestational maternal urine steroid markers of fetal Smith-Lemli-Opitz (SLO) syndrome (7-dehydrocholesterol 7-reductase deficiency). Steroids. 1999; 64(7): 446–452.
  34. Jezela-Stanek A, Małunowicz EM, Ciara E, et al. Maternal urinary steroid profiles in prenatal diagnosis of Smith-Lemli-Opitz syndrome: first patient series comparing biochemical and molecular studies. Clin Genet. 2006; 69(1): 77–85.
  35. Shackleton CH, Roitman E, Kratz L, et al. Dehydro-oestriol and dehydropregnanetriol are candidate analytes for prenatal diagnosis of Smith-Lemli-Opitz syndrome. Prenat Diagn. 2001; 21(3): 207–212.